
Kelun-Biotech's ADC Combo Hits Primary Endpoint in Lung Cancer Trial
A Phase III study has demonstrated that the antibody-drug conjugate sacituzumab tirumotecan, when paired with pembrolizumab, significantly improves progression-free survival in patients with PD-L1-negative non-squamous non-small cell lung cancer, marking a potential shift in the first-line treatment landscape for those with limited immune responses.
























